It appears from this announcement that the company is beginning...

It appears from this announcement that the company is beginning to backslide out of HCV - we're now hearing about "Biotron's HIV-1 and Hepatitis C virus (HCV) drug development programs" rather than HCV being the first mentioned as it generally has before. If you read it carefully you will also note they are only funded for current trial activities (one of which is completed), and the rebate will "support" a proposed Phase 2 HIV-1 trial, not fund it. As such, as J8 says, a CR is inevitable sooner rather than later.

Getting out of HCV sooner rather than later is important for holder's equity. I do wonder who they are using as scientific advisors. Hopefully some holders here are using the higher share price to reduce exposure to this early stage research group masquerading as an investment.